SRL Diagnostics hosts ‘International Gynecologic & Breast Cancer Symposium 2022’

The scientific and academic event took place on 20th November 2022

0
39
New Delhi: SRL Diagnostics, India’s leading diagnostic chain hosted an International Symposium on Gynecologic & Breast Cancer, featuring speakers from Cleveland Clinic. The scientific and academic event took place on 20th November 2022.
This interactive session brought together physicians, practitioners, and clinicians to gain insights on innovations in breast and gynecological cancer management from national and international subject matter experts.
Data from population-based registries suggest that cervix, uteri and breast are the most common cancer sites in women in India. About 50-60% of all malignancies in women are caused by 4 organs: the breast, the cervix uteri, corpus uteri and ovaries. Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India.
Speaking on the conference, Mr. Anand. K, Chief Executive Officer, SRL Diagnostics said “Despite cervical and breast cancer being entirely preventable through timely detection of precancerous lesions, there exists geospatial variations in cancer screening across districts in India. At SRL Diagnostics, our team of experts are undertaking some of the most nuanced cancer diagnosis workup each day and we are committed to usher in the best in onco-diagnostics.”
Adding his comments, Dr. Stephen Grobmyer, Institute Chair, Breast Surgical Oncology Institute, Cleveland Clinic Abu Dhabi said “cancers today are increasingly seen as diseases of the genome.  The characterization of genetic and protein abnormalities within a cancer now often determines how cancers are diagnosed and treated. Access to the latest approaches to tumor diagnosis and characterization can have a major impact on how patients are treated and the impact of treatments on patient outcomes.
Some of the topics that were discussed are new approaches to surgical management of breast cancer, evolving landscape of uterine and cervical cancer management, PD-L1 testing in gynecological neoplasms etc.
The session had a stellar line up of speakers including Dr. Stephen Grobmyer, Institute Chair, Breast Surgical; Dr. Stephanie Ricci, Staff Physician, Gynecologic Oncology, Oncology Institute from Cleveland Clinic, Abu Dhabi and Ms. Deepika Gandhi, the India Representative of Cleveland Clinic.
Speakers from Fortis Memorial Research Institute include Dr. A.K. Anand, Senior Director & Department Head, Radiation Oncology; Dr. Ankur Bahl, Senior Director, Medical Oncology &
Hematology; Dr. Rama Joshi, Principal Director & HOD, Gynae Oncology & Robotic Surgery and Dr. Vedant Kabra, Principal Director, Department of Surgical Oncology. Speakers from SRL Diagnostics include Dr. Kunal Sharma, Associate Director, Histopathology & COE, Dr. Priti Jain, Principal Histopathologist and Dr. Rekha Singh, Chief Histopathologist.